Google
RDY Stock Analysis — DR. REDDY’S LABORATORIES LTD ADR (Healthcare >> Drug Manufacturers - Specialty & Generic)
RDY FAQ
What is RDY's P/E ratio?
DR. REDDY’S LABORATORIES LTD ADR (RDY) currently trades at a P/E ratio of 0.30.
What is RDY's ROE?
DR. REDDY’S LABORATORIES LTD ADR reports a Return on Equity (ROE) of 8.65%.
What is RDY's dividend yield?
DR. REDDY’S LABORATORIES LTD ADR offers a dividend yield of 0.70%.
What is RDY's Quality Score?
Our AI rates RDY's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RDY?
Our AI Timing Score for RDY is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RDY belong to?
DR. REDDY’S LABORATORIES LTD ADR is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NYSE exchange
RDY AI Analysis Summary
Our AI summary for RDY: DR. REDDY’S LABORATORIES LTD ADR (NYSE), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.30, ROE of 8.65%, a dividend yield of 0.70%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.85
Price
0.02
(0.17%)
Day Change
|
|
|---|
RDY, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
171
|
| Magic Formula Rank by ROE |
171
|
| Magic Formula Rank by ROIC |
153
|
| Price | 11.85 |
| PBV / Sector |
0.03 / 3.22
GREAT
|
| Earning Per Share | 39.88 |
| PE / Sector |
0.30 / 29.79
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
35.51 M
GREAT
|
| Average 1W Daily Value |
33.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
58% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:24 |
| Symbol | RDY |
| Name | DR. REDDY’S LABORATORIES LTD ADR |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NYSE |
| Listed Shares | 833.00 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 9,854.39 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 8-2-337, Road No. 3, Hyderabad, India, 500034
Phone: 91 40 4900 2900
Website: https://www.drreddys.com
Employees: 27,527
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap